Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Prelude Therapeutics (PRLD) Leases (2023 - 2026)

Prelude Therapeutics' Leases history spans 4 years, with the latest figure at $26.8 million for Q1 2026.

  • On a quarterly basis, Leases fell 5.43% to $26.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.8 million, a 5.43% decrease, with the full-year FY2025 number at $27.2 million, down 5.35% from a year prior.
  • Leases hit $26.8 million in Q1 2026 for Prelude Therapeutics, down from $27.2 million in the prior quarter.
  • Over the last five years, Leases for PRLD hit a ceiling of $30.4 million in Q4 2023 and a floor of $26.8 million in Q1 2026.
  • Historically, Leases has averaged $28.6 million across 4 years, with a median of $28.5 million in 2024.
  • The widest YoY moves for Leases: up 5.35% in 2025, down 5.95% in 2025.
  • Tracing PRLD's Leases over 4 years: stood at $30.4 million in 2023, then dropped by 5.63% to $28.7 million in 2024, then dropped by 5.35% to $27.2 million in 2025, then fell by 1.42% to $26.8 million in 2026.
  • Business Quant data shows Leases for PRLD at $26.8 million in Q1 2026, $27.2 million in Q4 2025, and $27.5 million in Q3 2025.